By Michael McCaughan
There are plenty of big numbers associated with the Medicare prescription drug benefit:
Playing Offense in Part D: Three Aggressive Medicare Strategies Demand Pharma Attention
Humana thrilled CMS-and shocked its competitors-by offering stand-alone drug insurance plans under Medicare for less than $10 per month. Pharmaceutical manufacturers should applaud. Not all Part D strategies are equal for pharma companies. Manufacturers should compare Humana's approach to other aggressive bids by UnitedHealth and WellCare.
More from Market Access
More from Pink Sheet
• By
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
• By
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
• By
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.